Preview Mode Links will not work in preview mode

ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research

Apr 27, 2021

Current guidelines recommend implantable cardioverter-defibrillators (ICDs) in nonischemic cardiomyopathy (NICM) among patients with heart failure and ejection fraction ≤35%. Should this change? Should cardiac resynchronization therapy pacemakers be considered in patients with NICM and left bundle branch block? What were the data to support the use of ICDs for primary prevention in NICM? In this episode, Rachel Lampert, MD, moderates a debate between Michael R. Gold, MD, PhD, and Eric N. Prystowsky, MD, FACC, about whether primary prevention ICDs are still a valuable therapy in patients with NICM. For 20+ insider interviews like these every month with CME/MOC credit, subscribe to ACCEL at